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Abstract² The healing of soft tissue wounds and injury sites 
is a complex process requiring the participation of many 
different cells, tissues, proteins and tissue components in a co-
ordinated manner. We describe the development of regenerative, 
electrospun, bioresorbable advanced material tissue scaffolds 
providing three dimensional (3D) structure for cells involved in 
the repair of soft tissue injuries.  One product, ENWR7KHUL[
provides a micron-scale 3D architecture to enhance the 
recruitment of reparative cells onto this temporary support and 
LQ WKLV ZD\ WKH ERG\¶V FDSDFLW\ WR UHSDLU LWVHOI LV XWLOLVHG
EktoTherix and other electrospun tissue scaffolds have been 
translated from early stage laboratory work through 
manufacturing process development and clinical investigation. 
Keywords² electrospinning; scaffold; tissue repair; medical 
device translation; bioresorbable polymer 
I.  INTRODUCTION 
Over the past two decades there has been much research 
into the use of electrospun biomaterials for applications in 
regenerative medicine, drug delivery, and in vitro tissue 
modelling.  Although a promising technique for the 
manufacture of a wide variety of functional biomaterials 
proposed for use in almost all clinical specialties, complex 
technical challenges and regulatory requirements must be 
satisfied in order to develop clinically-acceptable products 
using this process.  Electrospinning uses high voltage to 
generate a large electric potential difference able to cause an 
electrically charged jet of polymer solution to be ejected from 
conducting needles towards a collector.  Electrostatic 
repulsion, a rapid whipping motion of the jet, and solvent 
evaporation all contribute towards significant narrowing of the 
jet as it travels towards the collector.  Very fine (10 nm to 10 
µm diameter) fibres are formed as the jet dries, and these 
accumulate on the collector resulting in highly porous 
materials with very large surface areas. 
Electrospinning offers a simple and convenient method for 
the manufacture of scaffolds that contain no biological 
material, using a range of cost-effective bioresorbable 
materials with a history of use in humans.  Since 2007 
Neotherix has been developing novel electrospun biomaterials, 
and has encountered and overcome a number of technical 
challenges in order to establish a reliable, scalable and 
commercially viable electrospinning process.  The technical 
solutions generated have allowed the completion of, to the 
best of our knowledge, the first clinical trial of an electrospun 
regenerative device [1]. 
The use of scaffolds in tissue regeneration and repair has 
been the subject of significant research and development effort 
in recent years.  Amongst other attributes, implanted scaffolds 
provide a three-dimensional (3D) porous framework for host 
cell attachment, proliferation and extracellular matrix 
GHSRVLWLRQ>@,QWKLVZD\WKH\DUHDEOHWRVXSSRUWWKHERG\¶V
own repair mechanisms, facilitating the repair, regeneration or 
replacement of diseased or damaged organs and tissues.  The 
use of bioresorbable polymeric materials selected, designed 
and fabricated in such a way as to provide a temporary 
architecture allows the development of tissues that 
approximate the structure and properties of native tissues. 
The clinical role and effectiveness of tissue scaffolds can 
be modified by the incorporation of bioactive agents to allow 
an enhanced range of features to be developed.  For example, 
scaffolds designed to support the cells involved in the healing 
process can also act as a vehicle for the delivery of bioactive 
agents directly to a site of injury in a controlled manner, 
avoiding the need for systemic administration with its 
associated toxicity [3]. Manipulating the scaffold composition 
affords control over the release profile, either to limit release 
in order to avoid high concentrations of potentially cytotoxic 
substances or to deliver relative high doses of agents directly 
to affected cells and tissues by virtue of the VFDIIROG¶V KLJK
surface area [4]. 
We have investigated the properties required of a porous 
bioresorbable scaffold for applications in soft tissue repair, the 
suitability of electrospinning as a process technology to realise 
the scaffold target design and characteristics and the feasibility 
of incorporating an agent to confer antimicrobial activity as an 
adjunct to the primary structural function of the scaffold. 
II. MATERIALS AND METHODS 
Neotherix uses a custom-built electrospinning rig, 
designed to have a highly variable configuration to satisfy the 
requirements of biomaterial research, while having the 
capacity to act as an early stage manufacturing rig following 
release of a product onto the market.  It can be set up in six 
different high voltage configurations: needles and target can 
be at positive, negative or zero potential (independently).  
Process settings can be independently varied including: 
Rotating target (earthed or 
high electric potential) 
Variable needle to target distance 
Horizontally traversing 
needle arm 
Polymer solution 
from pump 
Each needle arm contains a pair of needles (high 
electric potential or earthed) 
 
 
number of needles, potential difference, electric field polarity, 
collector diameter and collector rotation speed, needle to 
collector distance, and needle traversing rate (Fig. 1).  It is 
capable of simultaneously delivering more than one type of 
polymer solution for electrospinning.  Electrospun scaffold 
biomaterials were prepared using this rig according to 
methods described in several patent applications [5].  In the 
current preferred configuration, a sheet of 940 cm2 can be 
produced from which scaffold units of sizes appropriate to the 
target clinical application can be cut. 
Fig. 1. Schematic of electrospinning rig. 
Fig. 2. 6FDQQLQJ HOHFWURQ PLFURJUDSK RI 1HRWKHUL[¶ (NWR7KHUL[
poly(glycolic acid) tissue repair scaffold (scale bar represents 50 µm). 
Scaffolds have been characterised by a range of techniques 
including scanning electron microscopy (for example see Fig. 
2), capillary flow porometry, inherent viscosity and residual 
solvent analysis.  Cell populated scaffolds resulting from in 
vitro and in vivo experiments have been characterised by 
confocal microscopy, histology and analysis of resulting 
extracellular matrix composition.  See, for example, Fig. 3 
which shows fibroblast cells attached to a scaffold evaluated 
using the rat subcutaneous implant model. 
Fig. 3. Ability of scaffold to support growth of fibroblasts. Cells  (stained by 
haematoxylin and eosin) are shown attached and spread over a partially 
degraded scaffold after 5 days implantation using the rat subcutaneous model 
(x 20 magnification).  
Using this experimental and production set up, we have 
generated scaffolds targeted at the repair of acute and of 
chronic wounds, oral mucosal surgical sites (including 
infected or at risk of infection) and repair of fistula-in-ano.  In 
each case the polymer was chosen on the basis of its rate of 
bioresorption (and thus residency time) so that this 
approximated the expected duration during which cells would 
need 3D support.  Scaffolds electrospun from poly(glycolic 
acid; PGA), poly(lactic-co-glycolic) acid (PLGA) and 
polycaprolactone (PCL) were selected as being most suited to 
the various requirements of these different repair sites.  In 
each case the solvent was hexafluoro-2-propanol (HFIP).  
Antimicrobial activity was achieved by incorporation of a 
photosensitiser (PS) at the polymer solution stage so that it is 
encapsulated within the resultant fibres when electrospun (see 
examples in Table 1).  Subsequent release and activation using 
photodynamic therapy technology is expected to allow the 
translation of a scaffold with enhanced properties (e.g. 
antimicrobial activity) along the pathway from laboratory to 
clinic. 
TABLE I.  EXAMPLES OF SOME OF THE PHOTOSENSITISERS 
SUCCESSFULLY ENCAPSULATED WITHIN ELECTROSPUN FIBRES. 
Photoactive 
Agent 
Molecular 
Weight Chemical Structure 
Scaffold 
Image 
Erythrosine B 879.9 
 
 
Methylene 
blue 319.9 
 
 
Toluidine 
blue O 305.8 
 
 
 
III. RESULTS AND DISCUSSION 
Significant challenges exist in the development of any 
acellular bioresorbable tissue scaffold manufacturing 
technology [2,6,7].  Techniques that obtain scaffolds via the 
decellularisation of biological tissue (porcine, bovine, or 
human) [8,9,10] can result in tissues closely resembling the 
original tissues, and can have specific biological interactions 
with cells that are difficult to duplicate synthetically.  
However these materials require significant processing to 
remove almost all traces of material from the donor organism 
that may be pathogenic or trigger immune responses.  There is 
also little control over the bioresorption rate of these materials 
and the processing can significantly affect the mechanical 
properties of the resulting matrix. 
Synthetic scaffold materials offer greater potential for the 
tailoring of structural, chemical, and mechanical properties.  A 
wide variety of fabrication methods exist, including phase 
separation, freeze-drying, high-pressure spinning, gas-assisted 
spinning, and force spinning.  Although each of these 
techniques can have advantages when used for specific 
applications, none offer a broad range of advantages that 
would allow them to dominate electrospinning as a versatile 
method of scaffold manufacture. 
Self-assembly has also been used to generate 3D structures 
for use as scaffolds [11,12], but this approach is limited to use 
of specific precursor materials, and can result in scaffolds with 
poor mechanical properties.  The materials often have no 
established history of use in humans and can be expensive to 
manufacture.  Micro-moulding and rapid prototyping 
technologies have also been directed towards the fabrication 
of scaffolds [13,14].  While such technologies can allow 
precise control over the 3D architecture, it is difficult to 
achieve features smaller than tens or hundreds of microns in a 
truly 3D scaffold (i.e. not a thin film). 
A range of challenges were encountered in the 
development of our electrospun biomaterial scaffolds.  These 
include biological (e.g. cell attachment and interaction; low or 
zero cytotoxicity; minimal local tissue inflammation on 
implantation), chemical (e.g. rate of hydrolysis and 
bioresorption), structural (e.g. sufficient porosity to allow 
transport of nutrients and appropriate pore size to allow 
ingress of cells), processability (e.g. ability to control the 
electrospinning operation to yield scaffolds of target 
specification in a reproducible manner) and scalability (e.g. 
production of uniform scaffolds in sufficient volume to 
support a clinical investigation or market introduction). 
Challenges have been addressed in a systematic manner to 
provide technical and design solutions.  These include the 
optimisation of the 3D architecture for the cell types of 
interest, material selection, and selection of a suitable product 
sterilisation processes.  Process related challenges include 
determining how to solubilise a difficult to dissolve polymer, 
the best means for encapsulation of active compounds, 
methods for stabilising problematic formulations, and how to 
manufacture bilayer scaffolds.  Manufacturing challenges 
include the maintenance of process reliability and material 
quality whilst scaling up production volume, and the control 
of the manufacturing process to allow production of a sterile 
medical grade scaffold to international regulatory standards.  
Certification to ISO 13485 (Quality Management System 
(QMS) for the design and manufacture of Medical Devices as 
required for regulatory purposes) [15] was achieved in 2015 
[16] and can be applied to all Neotherix scaffolds intended for 
human use. 
The encapsulation of PS as exemplified in Table 1 into 
PGA electrospun fibres was found to have an attenuating 
effect on the resultant fibre diameter (Fig. 4).  The causative 
mechanisms for this alteration may operate at the stage of 
fibre production (e.g. as a result of changes in solution 
viscosity) and are the subject of further investigation. 
The successful translation of a novel biomaterial from 
laboratory to the clinic has been achieved on the completion of 
the First in Man (FIM) clinical investigation of EktoTherix for 
the repair of acute wounds [1].  A further scaffold product has 
now been approved to enter the FIM stage.  This translational 
journey also demonstrates the potential of electrospinning as a 
reliable, scalable and commercially viable process and the 
feasibility of application of the resulting scaffolds to a range 
of tissue repair targets.  This versatility has been further 
GHPRQVWUDWHGE\WKHDSSOLFDWLRQRI1HRWKHUL[¶VFDIIROGVWRWKH
generation of in vitro 3D tissue models, for example the 
modelling of bovine endometrium [17]. 
Fig. 4. Scanning electron micrographs of PGA scaffolds electrospun with PS 
(1 and 5%). Dimensions are mean fibre diameter measured by image analysis 
(images courtesy of Rina Haryani Binti Osman Basah, School of Dentistry, 
University of Leeds, UK). 
IV. CONCLUSIONS 
Neotherix has developed a reliable and scalable 
electrospinning process for the manufacture of safe and 
clinically-relevant implantable biomaterials.  A resorbable 
tissue repair scaffold was successfully translated from 
laboratory to clinic using an ISO 13485 certified process, 
culminating in the first clinical trial of an electrospun 
regenerative device despite a challenging regulatory 
environment.  Lessons learned in travelling this pathway are 
currently being applied to the development of other pipeline 
technologies, potentially leading to the translation of even 
more sophisticated electrospun biomaterials. 
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